In our study, local injection of in vivo-grade cholesterol-conjugated RIG-I si-circRNA-SORE significantly increased the sensitivity of sorafenib treatment in HCC mouse models, indicating the promising clinical application of siRNA-mediated regulation of circRNA-SORE in HCC patients. The gene discussed is RIGI; the disease is hepatocellular carcinoma.